Bacillary angiomatosis during pregnancy requires antibiotic therapy, but the choice of agent is directly shaped by fetal and maternal safety constraints that narrow the acceptable first-line options compared with non-pregnant patients.

Clinical scenario

This protocol addresses Bacillary angiomatosis in the setting of pregnancy. Pregnancy rules out certain antibiotic classes that are otherwise active against this condition, due to risks of hepatotoxicity and adverse fetal effects including permanent effects on developing fetal bones and teeth.

Treatment approach

First-line therapy relies on macrolide antibiotics, selected specifically to avoid agents contraindicated in pregnancy — the complete regimen, alternatives, and duration are covered in the full protocol.

Monitoring goals

Treatment response is followed serologically, with the target of achieving at least a fourfold decrease in anti-Bartonella IFA IgG antibody titers on sequential endpoint titers assessed every 6 to 8 weeks during treatment.

References

In pregnancy, erythromycin or an alternative macrolide should be used as first-line therapy (AIII) rather than tetracyclines (such as doxycycline) due to toxicity profile; third-generation cephalosporins may have efficacy but are second line.
Erythromycin treatment (or an alternative macrolide) should be used as first-line therapy (AIII) rather than tetracyclines (such as doxycycline) during pregnancy because of the increased risk of hepatotoxicity and the accumulation of tetracycline in fetal teeth and bones, resulting in dark, permanent staining of fetal teeth.
For patients with positive or increasing antibody titers, but with clinical improvement, treatment should continue until at least a fourfold decrease in the antibody titers is documented (CIII).

View source ↗

Treatment of Bacillary Angiomatosis in Pregnancy

Clinical scenario

Treatment approach

Monitoring goals

References